Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies
- 1 September 2017
- journal article
- review article
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 37 (5), 1461-1482
- https://doi.org/10.1148/rg.2017160162
Abstract
This review focuses on imaging of intra-abdominal adverse effects from targeted cancer therapies and advocates a conceptual framework for adverse effects that is based on the underlying molecular mechanisms and associated clinical outcomes. Targeted cancer therapies encompass an exponentially growing number of agents that involve a myriad of molecular pathways. To excel within this rapidly changing field of clinical oncology, radiologists must eschew traditional organ system–based approaches of cataloging adverse effects in favor of a conceptual framework that incorporates molecular mechanisms and associated clinical outcomes. Understanding molecular mechanisms that underlie imaging manifestations of adverse effects and known associations with treatment response allows radiologists to more effectively recognize adverse effects and differentiate them from tumor progression. Radiologists can therefore more effectively guide oncologists in the management of adverse effects and treatment decisions regarding continuation or cessation of drug therapy. Adverse effects from targeted cancer therapies can be classified into four categories: (a) category 1, on-target adverse effects associated with treatment response; (b) category 2, on-target adverse ...This publication has 91 references indexed in Scilit:
- Progression of RAS-Mutant Leukemia during RAF Inhibitor TreatmentThe New England Journal of Medicine, 2012
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With SunitinibJNCI Journal of the National Cancer Institute, 2011
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapyBritish Journal of Cancer, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- VEGF Inhibition and Renal Thrombotic MicroangiopathyThe New England Journal of Medicine, 2008
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002